Getting Wegovy in Aberdeen: a clear guide

You've searched Wegovy in Aberdeen, here is what that journey usually looks like

Most people who arrive at this search have already done a fair amount of reading. They know Wegovy is different from older weight-loss medicines, they have seen the clinical trial results, and they want to understand whether accessing it is genuinely practical when you live in the north-east of Scotland. The local picture matters. NHS Grampian's specialist weight management services are subject to the same national pressures as everywhere else, referral criteria are strict, and waits can stretch to many months. That reality pushes a lot of people towards the private route, which is entirely legal provided the supply comes from a pharmacy registered with the GPhC.

A GPhC-registered online pharmacy can serve patients anywhere in the UK, Aberdeen included. The consultation happens remotely, the prescriber reviews your answers the same day, and if treatment is approved, the medicine is dispatched that day for next-working-day delivery. You don't travel to a clinic. You don't wait weeks for a first appointment. The pen arrives tracked, in plain packaging, with no indication of what is inside. What matters is that the pharmacy is legitimately registered and that the prescriber is a real person reading your consultation, not software making an automated decision. You can verify any online pharmacy at the GPhC register.

The full overview of how Wegovy works covers the pharmacology in more detail, but the practical point for someone in Aberdeen is straightforward: geography is not the barrier it once was.

What the clinical evidence says, and what it means for your expectations

Wegovy's efficacy in clinical trials has been well-documented. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks on a 2.4mg weekly dose alongside lifestyle changes, and reported an average body-weight reduction of around 15%. Those are mean figures from a large trial population, individual responses vary, and a prescriber will always be clearest about what realistic progress looks like for your specific situation.

Wegovy works by acting on GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing hunger between meals. The effect on appetite is usually noticeable before significant weight changes appear. Treatment begins at a low dose (0.25mg) and is stepped up by the prescriber over several months until you reach the 2.4mg maintenance dose, or higher: the MHRA approved a 7.2mg maintenance dose in early 2026, initially delivered as three 2.4mg pens weekly, followed by approval of a dedicated single-dose 7.2mg pen in April 2026.

Common side effects are largely gastrointestinal: nausea, loose stools, constipation and reflux appear most often in the first weeks after starting or after a dose increase, and tend to settle as the body adjusts. Serious side effects are uncommon but include acute pancreatitis, the MHRA has highlighted this in its safety guidance for GLP-1 medicines. Severe, persistent stomach pain that radiates to the back warrants urgent medical attention.

Some people also ask about combining Wegovy with everyday habits, and whether drinking green tea alongside Wegovy is safe is one of the more common questions that comes up during treatment. For a broader look at semaglutide across its different formulations, the semaglutide overview draws these threads together.

Who Wegovy is licensed for, and where the NHS route stands in Scotland

The licensed eligibility criteria are set by the medicine's authorisation: adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol or obstructive sleep apnoea. A 2.5 kg/m² lower threshold can apply for some ethnic backgrounds under UK guidance. BMI alone does not determine whether a prescriber will approve treatment, your full health history, any contraindications and current medicines are all part of the clinical assessment.

On the NHS, NICE's recommendation for semaglutide (TA875) limits prescribing to a maximum of two years within specialist weight management services. Scotland has its own access framework through NHS Inform and NHS Grampian's commissioning decisions, and waiting times for those services are not predictable. The NHS England guidance on weight-management injections sets out the wraparound care expectations clearly, even though commissioning in Scotland is handled separately.

For people in Aberdeen who do not currently meet the NHS criteria or do not want to wait, a private prescription through a regulated pharmacy is the alternative. Questions about what injection schedule suits you, how doses are spaced and how to handle a delayed dose are all addressed with your prescriber during the process, the guidance on timing between Wegovy shots covers the general principles. There is no fixed national timeline for when NHS access in Scotland will broaden, so checking your eligibility now with a private prescriber is a reasonable step if you want to start sooner.

If you are weighing up what private treatment costs and what is included, the weight-loss treatment overview sets that out plainly, including what a transparent all-in price should cover.

How to get Wegovy through a registered online pharmacy, and what to check first

The process, done properly, is not complicated. You complete a medical consultation, questions about your BMI (verified, not self-reported), health history, current medicines and relevant conditions. A GPhC-registered Independent Prescriber reads your answers the same day. If treatment is clinically appropriate, a prescription is issued, and your order is dispatched. At nume, orders placed before noon on a working day are dispatched the same day once approved; a DPD tracking notification arrives on your phone, and the box that turns up is plain and unmarked.

Before choosing any online pharmacy for a Prescription-Only Medicine, check three things: that the pharmacy is on the GPhC register (the premises number should be displayed on the site and verifiable instantly), that a named human prescriber is doing the review, and that the price you are quoted includes the consultation and prescription, not just the medicine. Offers promising these medicines at prices far below the market rate, or from sellers who do not require clinical assessment, are a warning sign the MHRA has warned about publicly. Suspect sellers can be reported at Yellow Card.

If you are ready to have your eligibility assessed, check your eligibility with our prescribers, the consultation is free, and there is no obligation until a prescription is clinically agreed.